(P025) T3 Tumors and Breast Conservation

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

For patients with tumors greater than 5 cm, survival in the Medicare population remains similar between breast conservation and mastectomy, as it does for smaller primaries. Despite the exclusion from prospective randomized trials, breast conservation should remain a standard option for women with larger tumors when deemed clinically and cosmetically amenable to resection.

Richard J. Bleicher, MD, Karen Ruth, MS, Elin R. Sigurdson, MD, PhD, Marcia Boraas, MD, Penny Anderson, MD, John M. Daly, MD, Brian L. Egleston, PhD; Fox Chase Cancer Center

INTRODUCTION: Although breast conservation remains one standard for treatment of breast cancer, tumors > 5 cm have been consistently excluded from breast conservation clinical trials. While many surgeons perform breast conservation in select patients whose tumors are T3 primaries, very few small series have compared this with mastectomy for tumors > 5 cm. This study was performed to determine if survival remains equivalent between the two surgical options, using a large national dataset.

METHODS: Surveillance, Epidemiology, and End Results (SEER)-Medicare–linked cases were identified for patients aged ≥ 66 years undergoing breast conservation who had invasive noninflammatory, nonmetastatic breast cancer between 1992 and 2009. Propensity score-based adjustment was used to account for age, gender, race, year of diagnosis, Charlson comorbidity score, Elixhauser comorbidity index, income, education, marital status, SEER registry, urban/rural setting, United States (US) location, tumor size, histology, tumor grade, number of lymph nodes examined, number of positive lymph nodes, American Joint Committee on Cancer (AJCC) stage, administration of chemotherapy, and administration of radiotherapy.

RESULTS: There were 5,890 patients with tumors > 5.0 cm who underwent breast surgery, with 16.1% having breast conservation and 83.9% undergoing mastectomy. Mean age of the breast conservation and mastectomy patients was 77.6 and 77.3 years, and the mean tumor size was 7.97 vs 7.51 cm, respectively. While 28.4% of stage II patients with T3 tumors had breast conservation, only 8.1% of stage III patients did so. Over 64% of breast conservation patients and 68% of mastectomy patients had ≥ 5 years of follow-up. Use of breast conservation was associated with younger age at diagnosis, race, a history of other cancers, higher income, a more rural setting, region of the country, lower Charlson comorbidity index, histology, fewer nodes examined, fewer positive nodes, lower-grade tumors, lower AJCC stage, nonuse of chemotherapy, and the use of radiotherapy. Overall survival and breast cancer–specific survival, adjusted for demographic, tumor, and treatment factors, were not different between those having breast conservation and those having mastectomy (breast cancer–specific survival: subdistribution hazard ratio [SHR] = 1.07; 95% confidence interval [CI], 0.75–1.51; P = .71; overall survival: SHR = 0.92; 95% CI, 0.75–1.13; P = .43).

CONCLUSIONS: For patients with tumors > 5 cm, survival in the Medicare population remains similar between breast conservation and mastectomy, as it does for smaller primaries. Despite the exclusion from prospective randomized trials, breast conservation should remain a standard option for women with larger tumors when deemed clinically and cosmetically amenable to resection.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content